A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

New England Journal of Medicine

Volumn 363, Issue 7, 2010, Pages 620-628

  Zisman, David A ^a   Schwarz, M ^l   Anstrom, K J ^c,s   Collard, H R ^d   Flaherty, K R ^e   Hunninghake, G W ^f   de Andrade, J ^g   Frankel, S ^h,l   Kaplan, R ⁱ   Lancaster, L ^j,j   Raghu, G ^k,k,k   Utz, J P ^m,m   White, S R ^n,n   Zisman, D A ^a,q   Brown, K K ^l,l   Kaner, R J ⁱ   King, T E ^d   Lasky, J A ^o   Loyd, J E ^j,j   Martinez, F J ^e,e   Roman, J ^p,p   Ryu, J H ^m   Noth, I ^n,n   Chapman, J ^r   Olman, M ^r   Lubell, S ^r   Morrison, L D ^s   Steele, M P ^s   Haram, T ^s   Perez, R ^p   Perez, T ^p   Limper, A H ^m   Daniels, C E ^m   Meiras, K ^m   Walsh, S ^m   Kervitsky, D ^l   Ditta, S ^o   Thannickal, V J ^g   Stewart, M ^g   Lynch III, J P ^q   Calahan, E ^q   Lopez, P ^q   Golden, J A ^d   Wolters, P J ^d   Jeffrey, R ^d   Hogarth, D K ⁿ   Sandbo, N ⁿ   Strek, M E ⁿ   Brown, C ⁿ   Garic, I ⁿ   Maleckar, S ⁿ   Han, M L ^e   Moore, B ^e   Toews, G B ^e   Dahlgren, D ^e   Hayes, J ^k   Snyder, M ^k   Lawson, W ^j   Greer, R ^j   Mason, W ^j   Monroy, V ⁱ   Wang, M ⁱ   Lynch, D ^l   Colby, T ^t   Becker, R C ^s   Eisenstein, E L ^s   MacIntyre, N R ^s   Rochon, J ^s   Sundy, J S ^s   Davidson Ray, L ^s   Dignacco, P ^s   Edwards, R ^s   Anderson, R ^s   Beci, R ^s   Calvert, S ^s   Cain, K ^s   Gentry Bumpass, T ^s   Hill, D ^s   Ingham, M ^s   Kagan, E ^s   Kaur, J ^s   Matti, C ^s   McClelland, J ^s   Meredith, A ^s   Nguyen, T ^s   Pesarchick, J ^s   Roberts, R S ^s   Tate, W ^s   Thomas, T ^s   Walker, J ^s   Whelan, D ^s   Winsor, J ^s   Yang, Q ^s   Yow, E ^s   Reynolds, H Y ^u   Tian, X ^u   Kiley, J ^u   more..

^a Sansum Clinic   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l DEPARTMENT OF MEDICINE   (United States)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o TULANE UNIVERSITY   (United States)

^p EMORY UNIVERSITY   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r LERNER RESEARCH INSTITUTE   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t MAYO CLINIC   (United States)

^u National Jewish Health ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; PLACEBO; SILDENAFIL; OXYGEN; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ADULT; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOXEMIA; INFECTION; INFLUENZA; INTESTINE OBSTRUCTION; ISCHEMIC COLITIS; LUNG DIFFUSION CAPACITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXYGENATION; PEPTIC ULCER BLEEDING; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INFECTION; WALKING; AGED; BLOOD; EXERCISE TEST; LUNG FUNCTION TEST; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; AGED; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OXYGEN; PIPERAZINES; PULMONARY DIFFUSING CAPACITY; PURINES; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77956640423     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1002110     Document Type: Article

References (14)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
2. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
3. Nicholson AG. Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology 2002;41:381-91.
4. Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998;114:Suppl:208S-212S.
5. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
6. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897-9.
7. Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006;44:372-6.
8. Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005;25:370-7.
9. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2:105-10.
10. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304.
11. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36(R) Health Survey. Lincoln, RI: QualityMetric, 2000:27-48.
12. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70. [Erratum, Health Qual Life Outcomes 2010;8:4.]
13. Swigris JJ, Wamboldt FS, Behr J, et al. The 6-minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7.
14. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009;103:1430-5.